David Heal

Biography

 David is responsible for the consultancy and drug abuse liability testing services provided by RenaSci. Between 1997 and 2001 he was Head of Biology at BASF Pharma with global responsibility for Obesity Research. Between 1986 and 1997, David held the positions of Head of CNS Biology at BASF Pharma, Nottingham, and Section Leader, CNS Pharmacology, at Boots Pharmaceuticals where he directed research into the discovery of novel drugs for the treatment of a wide range of CNS disorders. During his career, he has had key roles in the successful US and European registration of 6 CNS drugs in the indications of obesity, schizophrenia, epilepsy and attention deficit hyperactivity disorder (ADHD). He has had extensive interactions with the EMA, FDA and many other regulatory agencies, including Japan. David was awarded a DSc in Pharmacology by King’s College, University of London, in 1998 and also holds a PhD in Biochemistry and a MSc in Analytical Chemistry from Chelsea College, London. He is Visiting Professor in the Department of Pharmacy and Pharmacology at the University of Bath and currently has a joint PhD student with Professor Sue Wonnacott and Dr Chris Bailey (University of Bath). His publication record consists of over 130 papers and 40 patents. In 2014, David was invited to become a Fellow of the Royal Society of Chemists (FRSC) in acknowledgment of his contributions to pharmacology and drug development.  

Research Interest

 Biology, Pharmacology